James A Kuzich
Overview
Explore the profile of James A Kuzich including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
54
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lim K, Wellard C, Talaulikar D, Tan J, Loh J, Puvanakumar P, et al.
EJHaem
. 2023 Aug;
4(3):639-646.
PMID: 37601874
The prognostic impact of t(11;14) in multiple myeloma (MM) needs to be better understood to inform future treatment decisions. The Australian Lymphoma Leukaemia Group embarked on a retrospective, observational cohort...
2.
Chan K, Gomez J, Cardinez C, Kumari N, Sparbier C, Lam E, et al.
Cancer Cell
. 2022 Sep;
40(10):1190-1206.e9.
PMID: 36179686
There is increasing recognition of the prognostic significance of tumor cell major histocompatibility complex (MHC) class II expression in anti-cancer immunity. Relapse of acute myeloid leukemia (AML) following allogeneic stem...
3.
Tedjaseputra A, Kuzich J, Thiagarajah N, Teh T, McClelland J, Rahman M, et al.
Leuk Lymphoma
. 2022 Jun;
63(11):2731-2734.
PMID: 35727162
No abstract available.
4.
Garciaz S, Guirguis A, Muller S, Brown F, Chan Y, Motazedian A, et al.
Cancer Discov
. 2021 Dec;
12(3):774-791.
PMID: 34862195
Significance: Ironomycin couples targeting of cellular metabolism with cell death by reducing mitochondrial iron, resulting in the alteration of mitochondrial metabolism and the activation of BAX/BAK. Ironomycin induces MOMP through...
5.
Tiong I, Dillon R, Ivey A, Kuzich J, Thiagarajah N, Sharplin K, et al.
Blood Adv
. 2021 Sep;
5(23):5107-5111.
PMID: 34555849
Monitoring of NPM1 mutant (NPM1mut) measurable residual disease (MRD) in acute myeloid leukemia (AML) has an established role in patients who are treated with intensive chemotherapy. The European LeukemiaNet has...
6.
Kuzich J, Kankanige Y, Guinto J, Ryland G, McBean M, Wong E, et al.
Bone Marrow Transplant
. 2021 May;
56(10):2582-2590.
PMID: 34031553
Identification of patients at risk of initial & recurrent cytomegalovirus (CMV) reactivation following allogeneic stem cell transplant (alloSCT) may help guide prophylactic strategies. T-cell receptor beta (TRB) deep sequencing was...
7.
Kuzich J, Heynemann S, Geoghegan N, Evelyn C, OMahoney S, Wilson S, et al.
Pathology
. 2021 Feb;
53(5):608-612.
PMID: 33618863
We reviewed haematological investigations for 43 patients treated at a single centre with alectinib, an inhibitor of anaplastic lymphoma kinase (ALK) which is considered standard first-line treatment for patients with...
8.
Jewell K, Kuzich J, Lee S, Trethowan R, Macdonell R, Schwarer A
Cancer Treat Res Commun
. 2021 Feb;
27:100341.
PMID: 33611091
No abstract available.
9.
Thompson E, Lim K, Kuzich J, McBean M, Westerman D, Tam C, et al.
Leuk Lymphoma
. 2020 Apr;
61(8):2024-2026.
PMID: 32319330
No abstract available.
10.
Kuzich J, Hutchison A, Lim K, Smallbone P, Denning K, Wright M, et al.
Leuk Lymphoma
. 2019 Jul;
60(14):3417-3425.
PMID: 31304820
We present an analysis of 98 consecutive patients with peripheral T-cell lymphoma (PTCL) treated over a 10-year period within Western Australia. The most common frontline therapies were CHO(E)P (47%), HyperCVAD...